Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.

doi:10.1097/JTO.0b013e31818ddcaa

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Dec 2008

Schneider Claus-Peter, Heigener David, Schott-von-Römer Kathrin, Gütz Sylvia, Laack Eckart, Digel Werner, Guschall Wolf-Rüdiger, Franke Andreas, Bodenstein Heinrich, Schmidtgen Claudia, Reck Martin

Abstract excerpt

INTRODUCTION: Relationships between clinical outcomes and epidermal growth factor receptor (EGFR)-related tumor markers were investigated in patients with advanced non-small cell lung cancer. METHODS: Patients with stage IIIB/IV non-small cell lung cancer (0-2 prior regimens) received erlotinib (150 mg PO per day). Response and survival were evaluated, and tumor samples were assessed by immunohistochemistry...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Germany

Share to Immunoenzyme Techniques

Share to Mitogen-Activated Protein Kinases

Share to Proto-Oncogene Proteins c-akt

Share to Quinazolines

Share to ras Proteins

Source

Open in PubMed

Identifiers

PMID: 19057271
DOI: 10.1097/JTO.0b013e31818ddcaa

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.PMID 19057271Read ↗

Erlotinib in lung cancer - molecular and clinical predictors of outcome.Semantic proximity Read ↗

Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients.Semantic proximity Read ↗

Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors.Semantic proximity Read ↗

Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.Semantic proximity Read ↗

Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).Semantic proximity Read ↗

Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.Semantic proximity Read ↗

A Prospective Observational Study Evaluating the Correlation of c-MET Expression and EGFR Gene Mutation with Response to Erlotinib as Second-Line Treatment for Patients with Advanced/Metastatic Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.Semantic proximity Read ↗

Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation.Semantic proximity Read ↗

Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).Semantic proximity Read ↗

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Concomitant driver mutations in advanced EGFR -mutated non-small-cell lung cancer and their impact on erlotinib treatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.